{"id":343828,"date":"2015-02-09T01:00:00","date_gmt":"2015-02-09T00:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/de-nouvelles-cibles-therapeutiques-sont-a-letude\/"},"modified":"2015-02-09T01:00:00","modified_gmt":"2015-02-09T00:00:00","slug":"de-nouvelles-cibles-therapeutiques-sont-a-letude","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/de-nouvelles-cibles-therapeutiques-sont-a-letude\/","title":{"rendered":"De nouvelles cibles th\u00e9rapeutiques sont \u00e0 l&#8217;\u00e9tude"},"content":{"rendered":"<p><strong>Une chose est s\u00fbre : Le pronostic de survie du cancer de la prostate m\u00e9tastatique r\u00e9sistant \u00e0 la castration (mCRPC) s&#8217;est am\u00e9lior\u00e9, passant en moyenne d&#8217;un peu plus d&#8217;un an (avant l&#8217;an 2000) \u00e0 pr\u00e8s de trois ans [1]. N\u00e9anmoins, les approches th\u00e9rapeutiques actuelles, qu&#8217;elles soient hormonales ou chimioth\u00e9rapeutiques, finissent par entra\u00eener une r\u00e9sistance, d&#8217;o\u00f9 l&#8217;importance de mieux comprendre le microenvironnement de la tumeur. Cela permettrait d&#8217;expliquer l&#8217;\u00e9volution des r\u00e9sistances et de d\u00e9finir de nouvelles cibles th\u00e9rapeutiques.  <\/strong><\/p>\n<p> <!--more--> <\/p>\n<p><em>(ag)<\/em>  Le microenvironnement du cancer de la prostate stimule la croissance et la propagation des cellules canc\u00e9reuses en supprimant la r\u00e9ponse immunitaire. Actuellement, on conna\u00eet d\u00e9j\u00e0 certains composants cellulaires et mol\u00e9culaires de ce processus, par exemple les cellules suppressives my\u00e9lo\u00efdes (MDSC), les macrophages associ\u00e9s aux tumeurs (TAM), les r\u00e9cepteurs Toll-like (TLR) et la prot\u00e9ine pro-inflammatoire S100A9.<\/p>\n<p>Les agents qui ont montr\u00e9 qu&#8217;ils pouvaient r\u00e9guler le microenvironnement des cellules tumorales sont, entre autres, l&#8217;ipilimumab (anti-CTLA4) ou le sipuleucel T (inoculation cellulaire autologue). Cette derni\u00e8re substance est la seule immunoth\u00e9rapie \u00e0 avoir montr\u00e9 une am\u00e9lioration de la survie globale dans le mCRPC [2]. Les r\u00e9sultats concernant l&#8217;ipilimumab sont moins prometteurs \u00e0 cet \u00e9gard et doivent plut\u00f4t \u00eatre consid\u00e9r\u00e9s comme une incitation \u00e0 poursuivre les recherches [3]. Le tasquinimod a \u00e9galement \u00e9t\u00e9 capable de renforcer la r\u00e9ponse immunitaire anti-tumorale et d&#8217;influencer l&#8217;accumulation et la fonction des MDSC dans des mod\u00e8les pr\u00e9cliniques &#8211; et ce, en se liant \u00e0 S100A9. La substance active est donc maintenant entr\u00e9e en phase III de d\u00e9veloppement.<\/p>\n<h2 id=\"les-os-sont-egalement-pertinents\">Les os sont \u00e9galement pertinents<\/h2>\n<p>Le microenvironnement osseux peut \u00e9galement \u00eatre utilis\u00e9 \u00e0 des fins th\u00e9rapeutiques. Ceci est d&#8217;autant plus important que de tr\u00e8s nombreux patients atteints de cancer de la prostate souffrent de m\u00e9tastases osseuses. Le d\u00e9nosumab, un inhibiteur de RANKL, est capable de retarder le d\u00e9lai avant le premier \u00e9v\u00e9nement associ\u00e9 au squelette (par ex. fracture, chirurgie osseuse, radioth\u00e9rapie) dans les \u00e9tudes cliniques [4]. Cependant, un b\u00e9n\u00e9fice pour la survie globale n&#8217;a pas encore \u00e9t\u00e9 d\u00e9montr\u00e9. Le radium 223, un \u00e9metteur alpha \u00e0 haute affinit\u00e9 osseuse, retarde l&#8217;apparition de m\u00e9tastases osseuses et am\u00e9liore en revanche significativement la survie globale.<\/p>\n<p><strong>Litt\u00e9rature :<\/strong><\/p>\n<ol>\n<li>Rathkopf DE, et al. : Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). Eur Urol 2014 Mar 6. pii : S0302-2838(14)00185-7. [Epub ahead of print].<\/li>\n<li>Kantoff PW, et al : N Engl J Med 2010 Jul 29 ; 363(5) : 411-422.<\/li>\n<li>Kwon ED, et al : Lancet Oncol 2014 Jun ; 15(7) : 700-712.<\/li>\n<li>Fizazi K, et al : Lancet 2011 Mar 5 ; 377(9768) : 813-822.<\/li>\n<\/ol>\n<p><em>Litt\u00e9rature compl\u00e9mentaire :<\/em><br \/>\n&#8211;&nbsp;&nbsp; &nbsp;Bellmunt J, et al : European Oncology &amp; Haematology 2014 ; 10(1) : 51-57.<\/p>\n<p>&nbsp;<\/p>\n<p><em>InFo ONKOLOGIE &amp; H\u00c4MATOLOGIE 2015 ; 3(1) : 2<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Une chose est s\u00fbre : Le pronostic de survie du cancer de la prostate m\u00e9tastatique r\u00e9sistant \u00e0 la castration (mCRPC) s&#8217;est am\u00e9lior\u00e9, passant en moyenne d&#8217;un peu plus d&#8217;un an&hellip;<\/p>\n","protected":false},"author":7,"featured_media":49227,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Immunosuppression dans le cancer de la prostate","footnotes":""},"category":[11523,11389,11549,11514],"tags":[48486,48480,48482,37671,48488,48487,48484],"powerkit_post_featured":[],"class_list":["post-343828","post","type-post","status-publish","format-standard","has-post-thumbnail","category-actualites","category-oncologie","category-rx-fr","category-urologie-fr","tag-ctla4-fr","tag-mcrpc-fr","tag-mdsc-fr","tag-prostate-fr","tag-radium-fr","tag-s100a9-fr","tag-tam-fr","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-09 03:51:41","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":343782,"slug":"si-stanno-esplorando-nuovi-target-terapeutici","post_title":"Si stanno esplorando nuovi target terapeutici","href":"https:\/\/medizinonline.com\/it\/si-stanno-esplorando-nuovi-target-terapeutici\/"},"pt_PT":{"locale":"pt_PT","id":343798,"slug":"novos-alvos-terapeuticos-estao-a-ser-explorados","post_title":"Novos alvos terap\u00eauticos est\u00e3o a ser explorados","href":"https:\/\/medizinonline.com\/pt-pt\/novos-alvos-terapeuticos-estao-a-ser-explorados\/"},"es_ES":{"locale":"es_ES","id":343811,"slug":"se-estan-explorando-nuevas-dianas-terapeuticas","post_title":"Se est\u00e1n explorando nuevas dianas terap\u00e9uticas","href":"https:\/\/medizinonline.com\/es\/se-estan-explorando-nuevas-dianas-terapeuticas\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/343828","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=343828"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/343828\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/49227"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=343828"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=343828"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=343828"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=343828"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}